Kame Alberto Galán-Huerta, Myriam Aseret Zamora-Márquez, Rómulo Omar Flores-Pérez, Paola Bocanegra-Ibarias, Daniel Salas-Treviño, Ana María Guadalupe Rivas-Estilla, Samantha Flores-Treviño, Sonia Amelia Lozano-Sepúlveda, Natalia Martínez-Acuña, Adrián Camacho-Ortiz, Eduardo Pérez Alba, Daniel Arellanos-Soto, Laura Nuzzolo-Shihadeh, Elvira Garza-González
{"title":"Association of the <i>Interleukin 1B</i>-31*C Proinflammatory Allele with the Severity of COVID-19 Patients: A Preliminary Report.","authors":"Kame Alberto Galán-Huerta, Myriam Aseret Zamora-Márquez, Rómulo Omar Flores-Pérez, Paola Bocanegra-Ibarias, Daniel Salas-Treviño, Ana María Guadalupe Rivas-Estilla, Samantha Flores-Treviño, Sonia Amelia Lozano-Sepúlveda, Natalia Martínez-Acuña, Adrián Camacho-Ortiz, Eduardo Pérez Alba, Daniel Arellanos-Soto, Laura Nuzzolo-Shihadeh, Elvira Garza-González","doi":"10.1089/vim.2022.0143","DOIUrl":null,"url":null,"abstract":"<p><p>Individuals with no known comorbidities or risk factors may develop severe coronavirus disease 2019 (COVID-19). The present study assessed the effect of certain host polymorphisms and viral lineage on the severity of COVID-19 among hospitalized patients with no known comorbidities in Mexico. The analysis included 117 unrelated hospitalized patients with COVID-19. Patients were stratified by whether they required intensive care unit (ICU) admission: the ICU group (<i>n</i> = 40) and non-ICU group (<i>n</i> = 77). COVID-19 was diagnosed on the basis of a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcription-polymerase chain reaction (RT-PCR) assay and clinical and radiographic criteria. The presence of the <i>IL1B-31</i> (T/C) polymorphism was determined for all patients using PCR and nucleotide sequencing. Genotyping of the <i>IL-4</i> (-590, T/C) and <i>IL-8</i> (-251, T/A) polymorphisms was performed by the amplification refractory mutation system-PCR method. Genotyping of <i>IL1-RN</i> was performed using PCR. Viral genome sequencing was performed using the ARTIC Network amplicon sequencing protocol using a MinION. Logistic regression analysis identified the carriage of <i>IL-1 B*-31</i> *C as an independent potential risk factor (odds ratio [OR] = 3.1736, 95% confidence interval [CI] = 1.0748-9.3705, <i>p</i> = 0.0366) for ICU admission and the presence of <i>IL-RN</i>*2 as a protective factor (OR = 0.4371, 95% CI = 0.1935-0.9871, <i>p</i> = 0.0465) against ICU admission. Under the codominant model, the CC genotype of <i>IL1B</i>-31 significantly increased the risk of ICU admission (OR: 6.38, 95% CI: 11.57-25.86, <i>p</i> < 0.024). The <i>IL1B</i>-31 *C-<i>IL-4</i>-590 *T haplotype increased the risk of ICU admission (OR = 2.53, 95% CI = 1.02-6.25, <i>p</i> = 0.047). The 42 SARS-CoV-2 genomes sequenced belonged to four clades, 20A-20D. No association was detected between SARS-CoV-2 clades and ICU admission or death. Thus, in patients with no known comorbidities or risk factors, the <i>IL1B</i>-31*C proinflammatory allele was observed to be associated with the risk of ICU admission owing to COVID-19.</p>","PeriodicalId":23665,"journal":{"name":"Viral immunology","volume":"36 4","pages":"241-249"},"PeriodicalIF":1.5000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Viral immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/vim.2022.0143","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 3
Abstract
Individuals with no known comorbidities or risk factors may develop severe coronavirus disease 2019 (COVID-19). The present study assessed the effect of certain host polymorphisms and viral lineage on the severity of COVID-19 among hospitalized patients with no known comorbidities in Mexico. The analysis included 117 unrelated hospitalized patients with COVID-19. Patients were stratified by whether they required intensive care unit (ICU) admission: the ICU group (n = 40) and non-ICU group (n = 77). COVID-19 was diagnosed on the basis of a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcription-polymerase chain reaction (RT-PCR) assay and clinical and radiographic criteria. The presence of the IL1B-31 (T/C) polymorphism was determined for all patients using PCR and nucleotide sequencing. Genotyping of the IL-4 (-590, T/C) and IL-8 (-251, T/A) polymorphisms was performed by the amplification refractory mutation system-PCR method. Genotyping of IL1-RN was performed using PCR. Viral genome sequencing was performed using the ARTIC Network amplicon sequencing protocol using a MinION. Logistic regression analysis identified the carriage of IL-1 B*-31 *C as an independent potential risk factor (odds ratio [OR] = 3.1736, 95% confidence interval [CI] = 1.0748-9.3705, p = 0.0366) for ICU admission and the presence of IL-RN*2 as a protective factor (OR = 0.4371, 95% CI = 0.1935-0.9871, p = 0.0465) against ICU admission. Under the codominant model, the CC genotype of IL1B-31 significantly increased the risk of ICU admission (OR: 6.38, 95% CI: 11.57-25.86, p < 0.024). The IL1B-31 *C-IL-4-590 *T haplotype increased the risk of ICU admission (OR = 2.53, 95% CI = 1.02-6.25, p = 0.047). The 42 SARS-CoV-2 genomes sequenced belonged to four clades, 20A-20D. No association was detected between SARS-CoV-2 clades and ICU admission or death. Thus, in patients with no known comorbidities or risk factors, the IL1B-31*C proinflammatory allele was observed to be associated with the risk of ICU admission owing to COVID-19.
期刊介绍:
Viral Immunology delivers cutting-edge peer-reviewed research on rare, emerging, and under-studied viruses, with special focus on analyzing mutual relationships between external viruses and internal immunity. Original research, reviews, and commentaries on relevant viruses are presented in clinical, translational, and basic science articles for researchers in multiple disciplines.
Viral Immunology coverage includes:
Human and animal viral immunology
Research and development of viral vaccines, including field trials
Immunological characterization of viral components
Virus-based immunological diseases, including autoimmune syndromes
Pathogenic mechanisms
Viral diagnostics
Tumor and cancer immunology with virus as the primary factor
Viral immunology methods.